Novartis to License VYGR's Capsid for Gene Therapy in Neurology
Swiss pharma giant Novartis NVS has agreed to license a novel capsid generated from Voyager Therapeutics, Inc’s VYGR capsid platform for use in a gene therapy program. Per Voyager, NVS will use thi...